The Outlook of Medical Devices in Central & Eastern Europe to 2016

Central & Eastern Europe is composed of a diverse range of markets, all at different stages of development. Markets throughout the region grew very rapidly until 2008, as many
countries joined the EU between 2004 and 2007. All have healthcare systems in great need of renovation and updating, and spending on new diagnostic equipment in particular has been very strong. Most new equipment is imported, as Russia, Poland, the Czech Republic, Ukraine and Hungary represent the five largest markets in the region. Slovenia is a small market, but has the highest per capita expenditure, on a par with much of Western Europe.

The Economic Situation
All countries in the CEE region were affected by the global economic crisis to some extent; Ukraine was particularly hard hit with its economy contracting by 14.8% in 2009. However, most of the region emerged from recession in 2010 and all CEE countries were exhibiting positive growth rates by 2011. The regional economy is expected to grow by an annual average of 3.1% between 2012 and 2016, although the ongoing eurozone crisis may negatively impact this rate. The CEE region contains export-dependent countries such as the Czech Republic and Hungary, which will be vulnerable to any depressed demand in the eurozone. However, financial assistance provided by the IMF has helped countries such as Romania to strengthen their economies and limit the effects of the recession on the health sector; overall demand for medical devices has therefore remained strong, particularly in the consumables field.

Explore Comprehensive list of Tables & Figures available in the report Central & Eastern Europe Medical Devices  Outlook Market

Report Details:

Published: March 2012

Price –US $3630                

 

Total health expenditure for the CEE region is projected to reach an estimated US$329.0 billion by 2016, equal to 6.7% of GDP. At present, only 29% of spending in the region is
private, but over 85% of this is composed of out-of-pocket payments. The area of private healthcare plans remains largely undeveloped within most markets. Slovenia, the wealthiest country per capita in the region, is the only state in which private plans have become a strong feature, representing almost half of total private spending.

Focus on market opportunities: Diagnostic Imaging
The table below shows the rise in demand for imported diagnostic imaging equipment since the end of the economic crisis, following a period of slow-moderate growth. Between 2006 and 2010, the CAGR for such equipment did not exceed 20% in the countries listed below; however, import performance was much more encouraging in the year ending October 2011, particularly in Romania and Poland where growth rates reached 47.8% and 34.0%, respectively.

Electrosurgical Devices Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

This new research provides key data, information and analysis on the global electrosurgical devices market. The report provides market landscape, competitive landscape and market trends information on the electrosurgical devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

Reasons to Buy

• Develop business strategies by understanding the trends and developments that are driving the electrosurgical devices globally.
• Design and develop your product development, marketing and sales strategies.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.
• What's the next big thing in the electrosurgical devices market landscape? - Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global electrosurgical devices market and the factors shaping it.

Explore Comprehensive list of Tables & Figures available in the report
Electrosurgical Devices Market

Report Details:
Published: February 2012
No. of Pages: 65
Price: Single User License – US$3995                Corporate User License – US$11985

Scope

• Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Key segments covered include Electrosurgical Disposables and Accessories and Electrosurgical Generators.
• Annualized market revenues data from 2004 to 2011, forecast forward for seven years to 2018. Company shares data for 2011.
• Qualitative analysis of key market trends, market drivers, and restraints by each segment within electrosurgical devices market.
• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Covidien, Erbe Elektromedizin, ConMed Corporation, Bovie Medical Corporation, Codman & Shurtleff, KLS Martin Group and B. Braun Melsungen.

Major points covered in Table of Contents of this report include

1 Table of Contents
2 Introduction 7
3 Electrosurgical Devices - Overview 8
4 Global Electrosurgical Devices - Market Characterization 11
5 Global Electrosurgical Devices Market - Segment Analysis 20
6 Global Electrosurgical Devices Market - Country Market Analysis and Forecasts 24
7 Electrosurgical Devices Market - Strategic Competitive Assessment 48
8 Electrosurgical Devices Market - Strategic Pipeline Assessment 53
9 Electrosurgical Devices Market - Mergers and Acquisitions Landscape 58
10 Appendix 61
1.1 List of Tables
1.2 List of Figures

Browse all Surgical Equipment Market Research Reports

Bard Medical Device Company Intelligence Report

Published:August 2011
No. of Pages: 48
Price: $515



  

Report Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Headquartered in Murray Hill, New Jersey, US, C.R. Bard (Bard) develops and manufactures medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the US and in more than 100 other countries, principally in Europe and Japan. In general, Bard’s products are intended to be used once and then discarded or implanted either temporarily or permanently.

Bard medical device healthcare industry report serves through five divisions – Bard Access Systems Inc, Bard Electrophysiology Division, Bard Medical Division, Bard Peripheral Vascular Inc (including Bard Biopsy Systems) and Davol Inc – and four major product group categories – vascular, urology, oncology and surgical specialties. The company also has a product group of ‘Other Products’.

Vascular – Bard’s vascular products are produced by Bard Electrophysiology and Bard Peripheral Vascular. The company’s vascular products cover a wide range of minimally-invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters; and fabrics, meshes and implantable vascular grafts.

Bard led the industry with the first angioplasty balloon catheter in 1980, giving cardiologists a safer and less costly alternative to open-heart procedures.

The January 2008 acquisition of the LifeStent range of stents from Edwards Lifesciences provided Bard with one of the broadest product offerings for peripheral vascular stenting.

The acquisition of Y-Med in November 2009 provided Bard with access to the VascuTrak catheter range.

More recently, the acquisition of FlowCardia in April 2010 expanded Bard’s portfolio of CTO endovascular products.

Urology – Bard claims to be the worldwide market leader in urological diagnostic and interventional products with a focus on urological drainage, continence and prostate disease management. Through its Bard Medical Division, the company has expanded its urology business to products in the areas of infection control, continence management, prostate management and catheter stabilisation.

The Foley catheter, which Bard introduced in 1934, remains one of the most important products in the urological field. Other urology products include: surgical slings used to treat stress urinary incontinence; faecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal.

Bard entered the brachytherapy business in March 1998 with the purchase of Proseed Inc, which offered a turnkey programme that allows a hospital to implement brachytherapy treatment with lower investment cost and financial risk.

The acquisition of Venetec International in 2006 gave Bard access to the StatLock range of catheter stabilisation devices, which are used primarily to secure peripheral intravenous catheters.

Oncology – Bard’s oncology products and services are provided through Bard Access Systems, Bard Biopsy Systems and Bard Medical Division. They are designed for the treatment and management of various cancers and other diseases and disorders. These include specialty access catheters and ports; vascular access ultrasound devices, dialysis access catheters and enteral feeding devices.

The acquisition of Dymax Corp extended Bard Access Systems’ portfolio to include ultrasound systems that allow physicians to have real-time visualisation of needle placement.

The purchase of SenoRx in July 2010 enabled Bard to expand its biopsy business into the stereotactic X-ray segments.
Surgical Specialties – Bard maintains a complete line of advanced surgical specialty products and services to complement its focus on disease state management. These products are produced by Bard Medical and Davol and include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopaedic, laparoscopic and gynaecological procedures and products for topical haemostasis.
Other Products – The other product group includes irrigation, wound drainage and certain original equipment manufacturer (OEM) products.
Bard employs approximately 11,700 people. In 2010, the company generated net earnings of US$510 million on revenues of US$2.72 billion. Net sales in the first six months of 2011 reached US$1.43 billion.

Bard's shares are traded on the New York Stock Exchange. In August 2011, ValueAct Capital Management, a San Francisco, California-based hedge fund, announced that it held 6.5% of the company's shares.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation

Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA).

Table of Contents
OVERVIEW.1
FINANCIAL REVIEW3
First Half 2011 Financial Results 3
Vascular .4
Urology 4
Oncology .4
Surgical Specialty .5
Other 5
2010 Financial Results.5
Vascular .7
Urology 7
Oncology .8
Surgical Specialty .9
Other 9
Five-Year Financial Data10
Outlook11
Employees.11
STRATEGIC FOCUS12
PRODUCTS13
Vascular.14
Urology16
Oncology 18
Surgical Specialty.20
RESEARCH AND DEVELOPMENT.22
Product Pipeline.22
Studies and Trials 24
RESILIENT Trial.24
Bard Flair Endovascular Stent Graft24
MANUFACTURING AND DISTRIBUTION26
AGREEMENTS .27
Acacia Research’s Catheter Flushing Division27
Covalon Technologies.27
RTI Biologics 28
Thermal Scalpel 28
Philips.28
Medegen29
Genzyme29
TyRx Pharma29
Enpath Medical30
CardioTech International (now AdvanSource Biomaterials)30
Mentor30
Tissue Science Laboratories.30
Mediwatch .31
Floreane Medical Implants 31
Specialized Health Products International .31
Endologix.31
Collagen (Allergan)31
IS Pharma (formerly Maelor)32
Integra LifeSciences32
MERGERS AND ACQUISITIONS . 33
Romedex International 33
SenoRx .34
Bard Sendirian.34
FlowCardia.34
PacerView Technologies Assets.34
Spire Corporation Assets34
Y-Med34
Brennen Medical.35
Specialized Health Products International.35
LifeStent Product Line from Edwards Lifesciences.35
Inrad.35
Venetec International.36
PST’s Self-Expanding Stent Assets.36
Genyx Medical.36
Sorenson Medical’s Closed Suction Catheter System 36
Onux Medical 37
Bridger Biomedical .37
Prostate Services of America, Amertek Medical and Alton Design.37
Biomedical Instruments and Products GmbH’s Biopsy Device37
Source Tech Medical37
Imagyn Medical Technologies - Rights to Seed Business.37
NMT Medical’s Vena Cava Filter Business38
Mill-Rose Laboratories .38
Surgical Sense .38
Biosearch Medical Products’ Intermittent Urinary Catheter Business 38
Navarre Biomedical 38
Dymax 38
ProSeed38
Endomatrix 39
Impra 39
American Hydro-Surgical Instruments .39
Vas Cath .39
Angiomed 39
Cardial 39
Bainbridge Sciences .39
JOINT VENTURES  40
Medicon40
MINORITY INVESTMENTS .41
Hydromer 41
DIVESTITURES  42
Endoscopic Technologies Business42
Cardiopulmonary Business 42
Intra-Aortic Balloon Catheter and Pump Business.42
Coronary Cath Lab Business 42
Neonatal Product Line .42
Surgical Suction Product Line42
Sani-Spec Product Line.43
Sure-Closure System 43
Inspiron Division .43
MedSystems Division .43
Shield Healthcare Centers .43
Electromedical Systems .43
LITIGATION 44
Product Liability Matters. 44
Hernia Repair Implant Products 44
Women’s Health Products 44
Vena Cava Filter Products. 45
Hologic.45
Atrium Medical and Endologix.45
Covidien.45
W.L. Gore & Associates45
St Francis Medical Center. 46
US Department of Health and Human Services, OIG. 46
KEY CORPORATE EVENTS47
List of Tables
SUMMARY OPERATING RESULTS.iii
Recent Key Events2
Bard - First Half 2011 Financial Results.3
Bard - First Half 2011 Sales by Product Area.3
Bard - First Half 2011 Sales by Geographic Area.3
Bard - Annual Financial Results, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20106
Bard – Five-Year Financial Summary.10
Bard – Product Contributions to Net Sales, 2006-201013
Key Vascular Products.14
Key Urology Products16
Key Oncology Products18
Key Surgical Specialty Products.20
Bard - Annual R&D Expenditure, 2006-201022
Bard – Principal Offices and Manufacturing Locations26
Agreements Summary27
Mergers and Acquisitions Summary.33
List of Charts
Bard - Annual Sales and Operating Income, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20107
Bard - 2010 Sales by Product Group13
Bard - Annual Vascular Product Sales, 2006-2010.14
Bard - Annual Urology Product Sales, 2006-201016
Bard - Annual Oncology Product Sales, 2006-201018
Bard - Annual Surgical Specialty Product Sales, 2006-201021

Kinetic concepts medical device company intelligence report

Published:July 2011
No. of Pages: 46
Price: $515


 

Report Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Founded in 1976, Texas, US-based Kinetic Concepts Inc (KCI) is a global medical technology company with primary business units serving the advanced wound care, regenerative medicine and therapeutic support systems markets. The company operates three business units:

Active Healing Solutions (AHS) - based at the company’s headquarters in San Antonio, Texas, the AHS business is focused on the development and commercialisation of advanced wound care therapies based on its negative pressure technology platform (NPTP), which employs negative pressure in a variety of applications to promote wound healing. NPTP comprises three primary product categories: negative pressure wound therapy (NPWT), negative pressure surgical management (NPSM) and negative pressure regenerative medicine (NPRM). NPWT, through the company’s V.A.C. therapy portfolio, currently represents the primary source of revenue for the AHS business. In addition, it continues to develop new products and therapies in NPSM and plans to launch NPRM products to broaden and diversify its NPTP revenue streams in the future. During 2010 and 2011, KCI’s latest NPWT product, the V.A.C.Via therapy system, was launched in the US and in select European markets, respectively. In addition, during 2010, the company launched the Prevena Incision Management System globally. Prevena is an NPSM product designed specifically for the management of surgically-closed incisions. In the acute care setting, KCI bills its customers directly for the rental and sale of its products. In the homecare setting, the company provides products and services to patients in the home and generally invoices third-party payers directly.

LifeCell - located in Branchburg, New Jersey, US, the LifeCell business is focused on the development and commercialisation of regenerative and reconstructive acellular tissue matrices for use in reconstructive, orthopaedic and urogynaecologic surgical procedures to repair soft tissue defects, as well as for reconstructive and cosmetic procedures. Existing products include human-based AlloDerm regenerative tissue matrix and porcine-based Strattice reconstructive tissue matrix in various configurations designed to meet the needs of patients and caregivers. The majority of LifeCell’s revenue is generated from the clinical applications of challenging hernia repair and post-mastectomy breast reconstruction, which is generated primarily in the US in the acute care setting on a direct billing basis. KCI continues efforts to penetrate markets with its other LifeCell products while developing and commercialising additional tissue matrix products and applications to expand into new markets and geographies.

Therapeutic Support Systems (TSS) - also based in San Antonio, the TSS business is focused on commercialising specialised therapeutic support systems, including hospital beds, mattress replacement systems, overlays and patient mobility devices. The business rents and sells products in three primary surface categories: critical care, wound care and bariatric care. Its critical care products, typically used in the ICU, are designed to address pulmonary complications associated with immobility; its wound care surfaces are used to reduce or treat skin breakdown; and its bariatric care surfaces assist caregivers in the safe and dignified handling of obese and morbidly obese patients, while addressing complications related to immobility. The TSS business moved into the patient mobility sector in January 2011 with the acquisition of TechniMotion Medical.

The addition of LifeCell to KCI's portfolio in May 2008 provided the company with additional long-term growth opportunities since changes in the NWPT market – the core of KCI’s business – mean that rivals are emerging with lower-priced, but equally effective, products to challenge KCI’s dominance of the field. Larger and more diversified companies are looking to buy those smaller companies with activities in NPWT – the purchase of BlueSky Medical by Smith & Nephew in 2007 is a good example – and, where it is able, KCI is defending itself by seeking legal opinion as to whether its rivals are infringing its NPWT patent rights. Indeed, KCI and Wake Forest University – which granted KCI an exclusive global licence to certain patents that are integral to the technology incorporated in V.A.C therapy products – are in dispute after a Federal District Court entered an order in a Smith & Nephew case invalidating Wake Forest patent claims. Since the beginning of 2011, KCI has refused to pay any further royalties to Wake Forest, which in turn, has filed a notice to terminate their licence agreement and demanded that KCI cease manufacturing and selling licensed V.A.C. products.

Overall, KCI rents and sells its products in more than 20 countries. The company has approximately 7,100 employees worldwide, operates R&D facilities in the US and the UK, and maintains manufacturing and engineering operations in the US, the UK, Ireland and Belgium. In 2010, KCI generated net income of US$256.1 million on revenue of US$2.1 billion. The AHS business accounted for 70% of revenue, the LifeCell business for 17% and the TSS business for the remaining 13%. In the first three months of 2011, KCI’s earnings were up 30% on a 3% increase in revenues.

On 12th July 2011, KCI entered into a definitive merger agreement under which a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of Canada Pension Plan Investment Board and Canada's Public Sector Pension Investment Board, would acquire KCI in a transaction valued at US$4.98 billion (or US$6.3 billion including KCI’s outstanding debt).

The US$68.50 per share in cash acquisition price represents a premium of approximately 21% to the one-month historical average stock price of US$56.49 to 5th July 2011 (one day prior to press speculation of a transaction) and a premium of 52% to the 12-month historical average stock price of US$45.01 through to 5th July 2011.

James R. Leininger, founder of KCI and former chairman, and certain shareholder parties related to or affiliated with him, which collectively hold approximately 11% of the company's outstanding shares, entered into a voting agreement with the consortium under which those shareholders agreed to vote their shares in favour of the transaction.
The transaction is subject to certain closing conditions, including the approval of KCI’s shareholders, regulatory approvals and the satisfaction of other customary closing conditions but is not subject to any condition with regard to the financing of the transaction. The investment consortium plans to further invest in the global medical products sector to expand KCI's core business, develop new products and extend into new geographies where it believes significant opportunities exist.

As provided for in the merger agreement, KCI was granted a 40-day "go-shop" window (expiring 21st August 2011) during which the company could solicit offers from other potential buyers. If all approvals and closing conditions are met and a superior offer failed to materialise, the deal with Apax-led group is expected to close in the fourth quarter of 2011.

Earlier in July, it was rumoured that KCI was the subject of a takeover approach by the US private equity group, Blackstone, and other investors including the global asset management company, Kohlberg Kravis Roberts.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation

Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.

Table Of Contents

OVERVIEW.1
Recent Key Events2

FINANCIAL REVIEW 3
First Half 2011 Financial Results3
AHS4
LifeCell5
TSS.5
2010 Financial Results.6
AHS9
LifeCell10
TSS. 12
Five-Year Financial Data14
Outlook15
Employees.16

STRATEGIC FOCUS17
PRODUCTS19
Product Overview19
AHS.19
NPWT Products21
NPSM Products23
GraftJacket Matrix.23
Competition.23
LifeCell.24
Products and Clinical Applications24
Allograft-Based Regenerative Tissue Matrix Products.24
Xenograft-based Reconstructive Tissue Matrix Products25
Competition.26
TSS26
Products and Clinical Applications27
Critical Care27
Wound Care27
Bariatric Care.28
Competition.28

RESEARCH AND DEVELOPMENT.29
R&D Facilities.29
R&D Expenditure.30
Studies and Trials.30
Transcontinental Wound Registry.30
RICH Study31
Trial Comparing NPWT between the KCI Wound V.A.C. Therapy System and Spiracur’s SNaP Wound Care System 31
Conexa Clinical Trial32
ABTAC Study.32

MANUFACTURING AND DISTRIBUTION33
AHS33
LifeCell33
TSS.33

AGREEMENTS 34
Wright Medical34
Novadaq Technologies.35
Carroll Hospital Group35
3M Health Care35
Hill-Rom36
NovaBay Pharmaceuticals36
Paul Hartmann.36
Avail Medical Products37
Wake Forest University.37

MERGERS AND ACQUISITIONS 38
TechniMotion Medical38
LifeCell38
BioMonde Assets.39
MedClaim.39
Polymedics.39
Beiersdorf-Jobst DVT Products39
RIK Medical.39
Equi-Tron Manufacturing.39
Ethos Medical Group.39
H.F. Systems.39
Trac Medical’s Access Assets.40
Clinical Systems.40
Medical Retro Design40
DIVESTITURES .41
KCI Insurance.41
KCI Financial Services41
KCI Therapeutic Services.41
LITIGATION.42
Wake Forest University.42
Smith & Nephew and Medela.42
Innovative Therapies Inc42
Boehringer and Convatec42
Medela, Mölnlycke Health Care and Smith & Nephew - Germany43
Smith & Nephew - Australia43
Smith & Nephew - Germany43
Smith & Nephew - France43
Smith & Nephew - UK.43
LifeCell44
OIG Investigation.44

KEY CORPORATE EVENTS45

List of Tables

SUMMARY OPERATING RESULTS.iii
KCI – First Half 2011 Financial Results3
KCI - First Half 2011 Revenues by Geographic Area.3
KCI - First Half 2011 Revenue by Business Segment and Geographic Area.4
KCI - AHS Business Segment Revenues, First Half 2011.4
KCI - LifeCell Business Segment Revenues, First Half 20115
KCI - TSS Business Segment Revenues, First Half 20115
KCI – Annual Financial Results, 2006-20106
KCI - Annual Revenues by Geographic Area, 2006-20107
KCI - Annual Revenue by Business Segment and Geographic Area, 2006-20108
KCI - AHS Business, Annual Financial Results, 2006-20109
KCI - LifeCell Business, Annual Financial Results, 2008-2010.10
KCI - TSS Business, Annual Financial Results, 2006-2010.12
KCI – Five-Year Financial Summary, 2006-201014
KCI – Annual R&D Expenditure, 2006-2010 30
Agreements Summary34
Mergers and Acquisitions Summary.38

List of Charts

KCI - Annual Revenue and Operating Income, 2006-2010.6
KCI - Annual Revenues by Geographic Area, 2006-20107
KCI - Annual Revenue by Business Segment, 2006-20108
KCI - AHS Business, Annual Revenue and Operating Income9
KCI - AHS Business, Annual Product Sales, 2006-2010.10
KCI - LifeCell Business, Annual Sales and Operating Income, 2008-2010.11
KCI - LifeCell Business, Annual Sales by Geographic Region, 2008-201011
KCI - TSS Business, Annual Revenues and Operating Income, 2006-201012
KCI - TSS Business, Annual Product Sales, 2006-201013
KCI – 2010 Revenue by Product Area19

Cooper Companies Medical Device Company Intelligence Report

Published:July 2011
No. of Pages: 36
Price: $515


 

Report Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

The Cooper Companies manufactures and markets speciality healthcare products through its CooperVision and CooperSurgical divisions.

CooperVision (CVI), headquartered in Pleasanton, California, US, manufactures and markets a broad range of contact lenses and, following its acquisition of Ocular Sciences in 2005, became one of the most successful players in this market. CVI’s primary offices are in the US and the UK and its manufacturing facilities are located in the US, the UK and Puerto Rico. Its principal medical device markets are the US, Europe and the Asia-Pacific region.

CooperSurgical (CSI), based on Trumbull, Connecticut, US, manufactures and markets medical devices, diagnostic products and surgical instruments and accessories for women’s healthcare, which are primarily used by gynaecologists and obstetricians. The company has mainly developed through small acquisitions, purchasing over 30 businesses over the last 20 years. The most recent acquisition was in April 2011, when CSI acquired Apple Medical, a developer of obstetric and gynaecology products. CSI’s primary objective is to service the obstetricians and gynaecologists in the US, since the company believes this is a more US-centric profession. However, the company does have a presence in Europe.
CVI’s three largest competitors are Johnson & Johnson’s Vistakon division, CIBA Vision (owned by Novartis) and Bausch & Lomb. Together with CVI, these companies represent almost 95% of the global soft contact lens market.

CSI competes primarily with smaller technology-driven companies that generally offer only one or two product lines. However, the company is now expanding into the significantly larger hospital and out-patient surgical procedure market, which is dominated by larger competitors such as Johnson & Johnson’s Ethicon Endo-Surgery and Ethicon Women’s Health and Urology companies, Boston Scientific, Gyrus ACMI (an Olympus company) and Covidien.

For the financial year ended 31st October 2010 (fiscal 2010), The Cooper Companies reported net income of US$112.8 million on net sales of US$1,158.5 million. This represented increases of 12% and 7%, respectively, when compared with fiscal 2009. CVI generated 84% of The Cooper Companies’ revenue, while CSI accounted for the remaining 16% of net sales.

As of June 2011, The Cooper Companies had a total of approximately 7,100 employees.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation

Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA). For more information please click on the link to, Medical Device Companies Analysis.

Table Of Contents

OVERVIEW.1

FINANCIAL REVIEW 2
First Half Fiscal Year 2011 Financial Results.2
CVI.3
CSI.4
Fiscal Year 2010 Financial Results5
CVI.6
CSI.8
Five-Year Financial Data9
Outlook10
Employees.11

STRATEGIC FOCUS12

PRODUCTS13
CVI13
CSI.16

RESEARCH AND DEVELOPMENT.22

MANUFACTURING AND DISTRIBUTION23
Manufacturing.23
Distribution.23

AGREEMENTS 24
CIBA Vision.24
Gebauer Medizintechnik24
Advanced Medical Optics.25
Rohto Pharmaceutical Company.25
Eyefinity.25
Welch Allyn25

MERGERS AND ACQUISITIONS 26
Apple Medical27
Asahikasei Aime Assets.27
American Medical Systems Assets.27
JLJ Medical Devices International27
Intuitive Surgical's Uterine Positioning System27
Wallach Surgical Devices28
Lone Star Medical Products28
NeoSurg Technologies/Inlet Medical28
Ocular Sciences28
Opti-Centre29
Milex Products.29
Argus Biomedical’s AlphaCor and AlphaSphere Products.29
SURx’ Radiofrequency Bladder Neck Suspension Technology29
Avalon Medical30
Prism Enterprises.30
SAGE BioPharma30
Ackrad Laboratories30
Orthometrix/Norland Medical Systems’ Bone Densitometry Business31
Biocompatibles Eye Care31
Medscand Medical.31
CL-Tinters Oy32
MedAmicus’ LuMax Fiber Optic Cystometry System32
MedaSonics32
Leisegang Medical’s Women’s Healthcare Products.32
BEI Medical Systems’ Women’s Healthcare Products.32
Aspect Vision Care Ltd.33
Marlow Surgical Technologies.33
Unimar33
RUMI Uterine Manipulator.33

MINORITY INVESTMENTS.34
Quidel.34

DIVESTITURES 35
CooperVision Surgical.35
Quidel.35
Hospital Group of America.35

LITIGATION.36
Rembrandt Vision Technologies .36
Internal Revenue Service36
Securities Litigation36

KEY CORPORATE EVENTS37

List of Tables

SUMMARY OPERATING RESULTS.iii
Recent Key Events1
The Cooper Companies – First Half Fiscal 2011 Financial Results.2
The Cooper Companies – First Half Fiscal 2011 Net Sales by Geographic Region.2
CVI – Selected First Half Fiscal 2011 Financial Results3
CVI – First Half Fiscal 2011 Revenues By Key Product.3
CVI – First Half Fiscal 2011 Sales by Geographic Area.3
CSI – Selected First Half Fiscal 2011 Financial Results.4
The Cooper Companies – Annual Financial Results, Fiscal Years 2006-2010.5
The Cooper Companies – Annual Net Sales by Geographic Region, Fiscal Years 2006-2010 5
CVI – Selected Annual Financial Results, Fiscal Years 2008-20106
CVI – Annual Revenues By Key Product, Fiscal Years 2008-2010.7
CVI – Annual Revenues by Geographic Region, Fiscal Years 2008-20107
CSI – Selected Annual Financial Results, Fiscal Years 2008-2010.8
The Cooper Companies – Five-Year Financial Summary, Fiscal Years 2006-2010.9
Soft Contact Lens Market by Region and by Competitor, Q1 201114
Global Soft Lens Market – Modality Breakdown by Region, Q1 201114
Global Soft Contact Lens Market – Estimated Five-Year Sales Trend by Product, Calendar Year 2010-2015  15
Global Soft Contact Lens Market – Estimated Five-Year Sales Trend by Region, Calendar Year 2010-2015 15
CVI – Key Contact Lens Brands, July 2011.15
CSI Market Shares, Fiscal Year 200918
CooperSurgical – Key Products, July 201119
Cooper Companies – Annual R&D Expenditure, Fiscal Years 2008-2010.22
Agreements Summary24
Mergers and Acquisitions Summary.26

List of Charts

The Cooper Companies - Annual Net Sales and Operating Income, Fiscal Years 2006-2010  5
The Cooper Companies - Annual Net Sales by Geographic Region, Fiscal Years 2006-2010.6
CVI - Annual Sales and Operating Income, Fiscal Years 2008-2010.6
CVI - Annual Net Sales by Geographic Area, Fiscal Years 2008-20107
CSI - Annual Net Sales and Operating Income, Fiscal Years 2008-2010.8
Global Soft Contact Lens Market by Competitor, Q1 2011.14
CSI – Office-based Sales by Product Type, Fiscal 201016
CSI – Hospital Sales by Medical Procedure/Segment, Fiscal 201017
CSI – Fertility Clinic Sales by Product Type, Fiscal 2010.17